Search Results

MRM Health NV announced it will present positive data for its lead asset, MH002, a live microbial consortium therapy for Inflammatory Bowel Diseases, in two oral presentations during the 2024 Digestive Disease Week® meeting, being held May 18-21, 2024 in Washington, D.C. at the Walter E. Washington Convention Center.

MRM Health, a clinical-stage biopharmaceutical company, announced that it has received regulatory and ethics committee approval to start an observational, cross-sectional clinical trial to study the role of the small intestinal microbiome in Parkinson’s Disease and to identify PD-specific microbial and metabolic fingerprints in small intestinal fluid and blood.

Creative Proteomics, a renowned leader in proteomics services, is making waves in the field of protein interaction studies with its cutting-edge GST Pull-Down Service.

MRM Proteomics, Inc. and Agilent Technologies Inc. are excited to announce their new co-marketing agreement aimed to further advance the capabilities of quantitative proteomic applications and thereby help the scientific community make impactful, novel scientific discoveries.

The global proteomics market size was evaluated at US$ 31.55 billion in 2023 and is expected to attain around US$ 110.13 billion by 2032, growing at a CAGR of 14.9% from 2023 to 2032

MRM Health NV reports positive topline results from its Phase 2a clinical trial with MH002 in mild-to-moderate Ulcerative Colitis.

MRM Health - a clinical-stage biopharmaceutical company focused on developing innovative microbiome-based biotherapeutics based on its proprietary and unique CORAL® platform technology - announced that it appointed Katja Conrath, PhD, as Chief Scientific Officer.